	RCB	
	PTO/98/30 (08-00) n 10/31/2002. QMB 0651-0031.	
or use through	1 10/31/2002. QMB 0651-0031.	

Approved for use through 10/31/2002. QMB 0651-0031.
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Index the Parent Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/449,907 # CHOCK	B
Filing Date	December 2, 1999	rg
First Named Inventor	SAKAMOTO et al.	2
Group Art Unit	3723	
Examiner Name	D. Nguyen	
Attorney Docket Number	107176-09004	

This	s a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.	
	NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may	
	wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for	
	the patent term adjustment provisions of the AIPA. See Changes to application Examination and Provisions Application Practice, Fine Rule, 65	
	Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which	
	established RCE practice.	

established RCE practice.		•				
1. Submission required under 37 C.F.R. § 1.114						
a. 🛭 Previously submitted						
i. Consider the amendment(s)/reply under 37 C.F.F	A Compiler than 1 1/1/1 1 1 07 0 5 D 0 4 440					
iii. Dother	_					
b. Enclosed	12/26/2001 TGEDAMU1 00000032	09449907				
i. Amendment/Reply	01 FC:179	,				
ii.	01 FG21/3	740.00 OP				
iii.		•				
iv. Other						
2. Miscellaneous						
a. Suspension of action on the above-identified applicat	ion is requested under 37 C.F.R.	§ 1.103(c) for				
	hall not exceed 3 months; Fee under 37 C.					
b.		4 .				
3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R.	§ 1.114 when the RCE is filed.	RECEIVED				
a The Director is hereby authorized to charge the follow Deposit Account No. 01-2300	ving fees, or credit any overpaym	ents, to a manage				
Deposit Account No. <u>01-2300</u>	, ,	DEC 27 2001				
i. RCE fee required under 37 C.F.R. § 1.17(e)	אברו	INOLOGY CENTER REA				
ii. ⊠ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) iii. □ Other)]EOI	INOLOGI OLITER NOR				
b. A Check in the amount of \$ 1,260 End	closed	•				
c. Payment by credit card (Form PTO-2038 enclosed)		• •				
SIGNATURE OF APPLICANT, ATTOR	NEY, OR AGENT REQUIRED					
Name (Print/Type) Jonathan A. Kidney	Registration No. (Attorney/Agent)	46,195				
Signature) J F NULLY	Date December 21, 2001					
CERTIFICATE OF MAILING O	OR TRANSMISSION)				
I hereby certify that this correspondence is being deposited with the United States Posta	al Service with sufficient postage as first cla	ass mail in an				
envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, Office on:	or facsimile transmitted to the U.S. Patent	and Trademark				
Name (Print/Type)						
reame (Fillo Lype)						

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

Date